Company Overview of Vantia Ltd
Vantia Ltd., a pharmaceutical company, develops small molecule drugs targeting areas of unmet medical needs. Its products include Fedovapagon (VA106483), a small molecule drug candidate for the treatment of nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate; and VA111913, a small molecule drug for the treatment of dysmenorrhea, a condition caused by abnormal contractions of the uterus and constriction of uterine blood vessels during menstruation that causes abdominal cramping and pain. Vantia Ltd. was incorporated in 2007 and is based in Southampton, United Kingdom.
Southampton Science Park
Southampton, SO16 7NS
Founded in 2007
44 11 7916 7693
44 23 8001 5945
Key Executives for Vantia Ltd
Similar Private Companies By Industry
|Abbey Pharma Limited||Europe|
|Absynth Biologics Limited||Europe|
|Acacia Pharma Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Vantia Ltd, please visit www.vantia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.